of >100 μM for 1 and 10.8 μM for 2). Ir-Cl hydrolysis is rapid for both complexes (hydrolysis equilibrium reached in < 5 min at 278 K). Complex 2 forms adducts with both 9-ethylguanine (9-EtG) and 9-methyladenine (9-MeA), but preferentially with 9-EtG when in competition (ca. 85% of total Ir after 24 h). The X-ray crystal structure of [(η 5 -C 5 Me 5 )Ir(phpy)(9-EtG-N7)]NO 3 ·1.5CH 2 Cl 2 confirms N7 binding to guanine.
Introduction
Organometallic complexes offer rich versatility for the design of anticancer agents. 1 Iridium complexes are best known for their inertness, 2 and indeed inert organometallic Ir III scaffolds are finding use as potent enzyme inhibitors. 3 The half-sandwich fragment {Cp*Ir III } (Cp* = pentamethylcyclopentadienyl) has been used as a stabilizing entity in many organometallic iridium complexes. 4 By suitable choice of the other ligands, relatively reactive Cp* Ir III complexes can be designed. (concentrations at which 50% of the cell growth is inhibited) all > 100 μM. 5 Also Cp* PTA iridium(III) complexes (PTA = 1, 3,5-triaza-7-phosphatricyclo-[3.3.1 .1]decane), 7 and Cp* pyTz iridium(III) complexes (pyTz = 2-(pyridine-2-yl)thiazole), 8 are reported to be inactive against A2780 cells (IC 50 values > 300 μM). Sheldrick et al. have shown that activity can be switched on by incorporating a DNA intercalator (N,N-chelating polypyridyl ligand) into some Cp* Ir III complexes. 9 Here we introduce a different switch involving a single atom change (C − for N) in a chelating 2,2′-bipyridine ligand to afford a neutral complex.
Cyclometallated organometallic complexes incorporating C,N-chelating ligands have attracted much attention because of their wide applications in both catalysis and luminescence. 10 However, few such previous studies have involved their anticancer activity. 11 In the work reported here, we compare the structure, reactivity and cancer cell cytotoxicity of Cp* Ir III complexes containing a neutral N,N-bound 2,2′-bipyridine (bpy) chelating ligand and an anionic C,N-bound 2-phenylpyridine 3 (phpy) ligand. We have studied the hydrolysis, nucleobase binding, and hydrophobicity (octanol/water partition), and attempted to relate these to their activity towards A2780 ovarian cancer cells. This appears to be the first report of an active Ir III anticancer complex containing both Cp* and a C,N-chelating ligand. This class of iridium complexes is attractive for development as new anticancer agents. 
Experimental Section
Materials. IrCl 3 ·nH 2 O, 9-ethylguanine (9-EtG), 9-methyladenine (9-MeA), 2,2′-bipyridine, 2-phenylpyridine, octan-1-ol (≥ 99%), and NaCl (> 99.999%) were purchased from Sigma-Aldrich. Mo Kα radiation. Absorption corrections were applied using ABSPACK. 13 The crystals were mounted in oil and held at 100(2) K with the Oxford Cryosystem Cobra.
The structures were solved by direct methods using SHELXS (TREF) 14 with additional light atoms found by Fourier methods. Complexes were refined against F 2 using SHELXL, 15 and hydrogen atoms were added at calculated positions and refined riding on their parent atoms.
Crystallographic data are shown in Table S1 , and selected bond lengths and angles are listed in Table S2 calculations. Geometry optimization calculations for complexes 1 and 2, their aqua derivatives and their 9-ethylguanine (9-EtG) and 9-ethyladenine (9-EtA) adducts were performed in the gas phase with the gradient-corrected correlation functional PBE0. were used for the Ir atom and the 6-31G** basis set was used for all other atoms. 19 The nature of all stationary points was confirmed by performing a normal-mode analysis. Electrostatic potential surfaces (EPSs) for complexes 1 and 2, their aqua derivatives and their 9-EtG and 9-EtA adducts were calculated and mapped on electron density (isovalue 0.04) of the molecules. The electrostatic potential is represented with a color scale ranging from red (-0.500 au) to blue (0.500 au). DFT results are summarized in the Supporting Information section.
Interactions with Nucleobases. DDW to freshly prepare calibrants at concentrations 1000, 800, 400, 200, 100, 50, 10, 1 and 0.1 ppb. The ICP-MS instrument was set to detect 193 Ir with a typical detection limit of ca. 8 ppt using no-gas mode. L-glutamine, and 1% penicillin/streptomycin). All cells were grown at 310 K in a humidified atmosphere containing 5% CO 2 . Stock solutions of the Ir III complexes were firstly prepared in DMSO to assist dissolution (maximum final DMSO concentration 1.25%), and then diluted into 0.9% saline and medium (1:1). After plating 5000 A2780 cells per well on day 1, Ir III complexes were added to the cancer cells on day 3 at concentrations ranging from 0.5 μM to 100 μM. Cells were exposed to the complexes for 24 h, washed with PBS, supplied with fresh medium, allowed to grow for three doubling times (72 h), and then the protein content (proportional to cell survival) measured using the sulforhodamine B (SRB) assay. 20 The standard errors are based on two independent experiments carried out in triplicate.
Results and Discussion
We have Table 1 and are in good agreement with the reported X-ray crystal structures. 4a,12 In complex 2, the chelating ligand is closer to the Ir III center than in complex 1; a short Ir-C(phenyl) distance causes elongation of the Ir-Cl bond as well as the Ir-Cp*(centroid) distance (Table 1) . The same features are observed for the aqua adducts of complexes 1 and 2 (Table S3) , and their 9-EtG and 9-EtA adducts (Tables S4 and S5 , respectively). Details of the frontier orbitals and electrostatic potential surfaces (EPSs) of complexes 1 and 2, their aqua adducts, and their 9-EtG and 9-EtA adducts are in the Supporting Information (Table S6 , S7, S8 and Figure S1 ). No significant differences or unexpected features are observed for the frontier orbitals of these derivatives or for 8 their EPSs.
Hydrolysis. Hydrolysis of M−Cl bonds is often an activation step for transition metal anticancer complexes. 21 We have previously reported that complex 1 undergoes rapid hydrolysis. 5 The hydrolysis based on 1 H NMR peak integrals are shown in Table 2 . isolated, and the X-ray crystal structure determined, which confirmed that 9-EtG is bound through N7 (Figure 2A) . The nitrate counter ion shows H-bonding to a 9-EtG ligand, with distances of 1.987 ( (Table S5 ).
The N7 atoms of G and A are accessible to metals, such as Pt in cisplatin, 25 for coordination in the major groove of DNA, whereas N1 of A is involved in
Watson-Crick base-pairing. Complex 2 reacted with guanine via N7, and formed adenine adducts via N1 and N7, with 4(N1) being the major adenine adduct. In addition, complex 2 has a higher affinity for guanine compared to adenine. Binding to guanine may therefore play a more significant role in its cytotoxicity. confirms coordination of 9-MeA through N1 as the major binding mode.
13
Compared with the C,N-chelated 2-phenylpyridine complex 2, which binds significantly to both nucleobases, the N,N-chelated 2,2′-bipyridine complex 1 formed an adduct only with 9-EtG (61%), and not with 9-MeA after 24 h (Table 2) , indicating weaker binding to both guanine and adenine bases. Table 2 ), is ca.
14 38 times smaller than that of the 9-EtG adduct. Competition between equal molar amounts of 9-EtG and 9-MeA for complex 2 (0.4 mM) in 10% MeOD-d 4 /90% D 2 O at 310 K (pH* = 7.4) gave rise to the 9-EtG adduct as the major product (ca. 85%) after 24 h, confirming the higher affinity for the nucleobase 9-EtG.
Some Ru II and Ir III complexes containing N,N-chelating ligands such as ethylenediamine and 1,10-phenanthroline have little affinity for adenine residues. 5, 27 In contrast, organometallic complexes containing N,O-chelating ligands or O,O-chelating ligands such as picolinate and acetylacetonate bind to both guanine and adenine residues. 5,6c,28 However, some Os II complexes containing picolinate derivatives show a strong preference for adenine. 29 The chelating ligands in these complexes appear to play an important role in the recognition of nucleobases, interacting especially with the C6O of guanine or the C6NH 2 of adenine, which can be rationalized in terms of H-bonding, non-bonding repulsive interactions between the chelating ligand and nucleobase substituents, and the electronic properties of the various nucleobase coordination sites. 30 The chelating ligands in the present work also have a significant effect on the selectivity of nucleobase binding. Complex 1 containing N,N-chelating 2,2′-bipyridine reacted only with 9-EtG, whilst complex 2 containing C,N-chelating 2-phenylpyridine formed both 9-EtG and 9-MeA adducts, preferentially binding to 9-EtG when in competition, which may result from the steric hindrance of the NH 2 group at the 6-position of the adenine ring. Some Pt II antitumor complexes bearing C,N-chelating ligands also show strong binding to 9-EtG. Table S5 .
Partition Coefficients (log P). Lipophilicity often correlates with cytotoxic potency and has therefore been used extensively in structure-activity correlations.
32
The octanol-water partition coefficients (log P) for complexes 1 and 2 were determined and are listed in Table 2 . Instead of water alone, 0.2 M NaCl was used to suppress hydrolysis of the complexes. Complex 1 is positively-charged and shows a negative log P value of -0.95 (partitions preferentially into water ca. 10-fold), whilst the neutral complex 2 is much more hydrophobic with log P value of 1.57 (partitions preferentially into octanol ca. 30-fold), Table 2 . The difference in partition coefficient between complexes 1 and 2 is thus directly related to their difference in charge.
The hydrophobicity and cancer cell activity correlate significantly in this study. 33 The log P value of 1.57 for complex 2 is within this range, whilst the log P of -0.95 for complex 1 is more negative, i.e. the complex 1 may be too hydrophilic for optimum drug-like properties.
Cytotoxicity. The cytotoxicity of complexes 1 5 and 2 towards A2780 human ovarian cancer cells was investigated, 
Conclusions
The goal of the present study was to design Cp* Ir Supporting Information Available: Details of X-ray crystallographic data, bond lengths and angles (Table S1 and S2), calculated bond distances for all derivatives of complexes 1 and 2 (Tables S3-S5) , electrostatic potential surfaces (EPSs) for complexes 1, 2, and all their derivatives (Table S6) , frontier orbitals of complexes 1, 2 and all their derivatives (Table S7 , S8, figure S1 ), H-bond of complex 3 (Table S9) , ESI-MS studies of binding to nucleobases ( Figures S2, S3 ), complete reference (16), and X-ray crystallographic data in CIF format. This material is available free of charge via the Internet at http://pubs.acs.org.
